<DOC>
	<DOCNO>NCT01476904</DOCNO>
	<brief_summary>E004-C2 continuation E004-C safety evaluation additional 3 month able assess 6-month safety profile E004 ( epinephrine inhalation ) versus placebo double-blinded manner .</brief_summary>
	<brief_title>Safety Study Adolescent Adult Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>Only subject successfully complete E004C study within last 135 day actively enrol current study E004C time study extension initiation Male female asthma patient age 12 75 year Patients document asthma , require inhale epinephrine beta 2agonist treatment No significant change asthma therapy asthmarelated hospitalization emergency visit , within 4 week prior Screening Demonstrating satisfactory technique use metereddose inhaler hand hold peak expiratory flow meter Female patient childbearing potential must nonpregnant nonlactating Screening throughout study , must use acceptable method contraception study A smoke history 10pack year , smoke within 12 month screen Any current past medical condition , per investigator discretion , might significantly affect response study drug , asthma Concurrent clinically significant disease Known intolerance hypersensitivity component study drug Recent infection respiratory tract , screen Use prohibit medication Having investigational drug/device study last 30 day prior screen Known highly suspect substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Bronchial Asthma</keyword>
	<keyword>Shortness breath</keyword>
</DOC>